Glutamine / L-Glutamine

ID: glutamine

Aliases: L-glutamine, glutamine, Endari

Type: compound

Route/form: oral supplement unless otherwise specified

Status: food_or_supplement_and_approved_drug_context

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, human_rct_negative, label, meta_analysis

Linked sources: 5

Broad outcomes: Gut / immune / inflammation, Longevity / mitochondrial / redox, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• conditionally essential amino acid
• nitrogen transport and glutathione precursor biology
• intestinal epithelial and immune-cell fuel
• sickle red blood cell redox support

Optimization domains

• nutrition
• muscle
• recovery
• gut barrier
• immune
• sickle cell disease
• redox
• supplement

Research basis

• L-glutamine has a real label-backed clinical anchor: Endari is approved to reduce acute complications of sickle cell disease in adults and pediatric patients 5 years and older.
• It belongs in nutrition/recovery maps because glutamine is central to nitrogen transport, gut epithelial fuel, immune-cell metabolism, and redox biology during stress states.
• Human sport and resistance-training sources make the boundary clear: glutamine is plausible biology, but not a reliable drug-like hypertrophy or performance enhancer.

Limits, risks, and missing evidence

• The sickle-cell indication does not validate general wellness, gut-healing, immune-boosting, recovery, or muscle-gain claims in healthy users.
• Clinical-trial and meta-analytic sport evidence is mixed to negative for broad athletic performance, body composition, and resistance-training adaptation outcomes.
• Prescription-dose and disease-context use should not be collapsed with casual supplement use; renal/hepatic impairment, pregnancy/lactation gaps, and oncology/critical-illness context require source-specific interpretation.

Risk flags

• approved drug context
• supplement
• indication specific
• not hypertrophy proven
• mixed sports evidence
• renal hepatic context
• pregnancy lactation data gap

Linked papers, labels, and reviews

1. DailyMed label: ENDARI (L-glutamine oral powder)
   label / dailymed_endari_label
   Official L-glutamine label for reducing acute complications of sickle cell disease in patients 5 years and older; anchors dosing, adverse reactions, population gaps, and disease-specific scope.
2. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease
   human_rct / pubmed_lglutamine_scd_phase3_2018
   Randomized phase 3 sickle-cell disease trial behind the label context; does not establish general recovery or muscle-performance effects.
3. The effect of glutamine supplementation on athletic performance, body composition, and immune function: A systematic review and a meta-analysis of clinical trials
   meta_analysis / pubmed_glutamine_sports_meta_2019
   Clinical-trial meta-analysis for sport/body-composition/immune claims; useful for showing broad performance claims are limited and context dependent.
4. Effect of glutamine supplementation combined with resistance training in young adults
   human_rct_negative / pubmed_glutamine_resistance_training_2001
   Randomized resistance-training trial in young adults; useful as a direct caution against treating isolated glutamine as a reliable hypertrophy adjunct.
5. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome
   human_rct / pubmed_glutamine_postinfectious_ibs_2019
   Gut-specific randomized trial in postinfectious IBS-D with increased intestinal permeability; supports narrow gut-barrier context without generalizing to all GI claims.